 Whitney Goldner
Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 21 | 2025 | 350 | 5.650 |
Why?
| | Thyroidectomy | 9 | 2024 | 92 | 1.300 |
Why?
| | Cancer Survivors | 2 | 2025 | 337 | 1.210 |
Why?
| | Thyroid Nodule | 4 | 2025 | 57 | 1.170 |
Why?
| | Thyroid Gland | 5 | 2024 | 89 | 1.110 |
Why?
| | Pesticides | 5 | 2019 | 59 | 1.090 |
Why?
| | Hypothyroidism | 4 | 2025 | 67 | 0.920 |
Why?
| | Thyroid Diseases | 4 | 2025 | 44 | 0.860 |
Why?
| | Survivorship | 1 | 2024 | 57 | 0.810 |
Why?
| | Fatigue | 1 | 2025 | 363 | 0.780 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 153 | 0.770 |
Why?
| | Adenocarcinoma | 4 | 2023 | 920 | 0.730 |
Why?
| | Societies, Medical | 5 | 2025 | 898 | 0.710 |
Why?
| | Carcinoma | 3 | 2025 | 224 | 0.710 |
Why?
| | Agriculture | 3 | 2019 | 93 | 0.700 |
Why?
| | Sleep Wake Disorders | 1 | 2025 | 310 | 0.690 |
Why?
| | Hormone Replacement Therapy | 3 | 2025 | 107 | 0.680 |
Why?
| | Vitamin D | 4 | 2012 | 403 | 0.620 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 733 | 0.610 |
Why?
| | Hyperglycemia | 4 | 2021 | 379 | 0.550 |
Why?
| | Hypophosphatasia | 1 | 2018 | 5 | 0.550 |
Why?
| | Occupational Exposure | 4 | 2019 | 355 | 0.540 |
Why?
| | Agricultural Workers' Diseases | 2 | 2018 | 29 | 0.530 |
Why?
| | Alkaline Phosphatase | 1 | 2018 | 144 | 0.520 |
Why?
| | Quality of Life | 3 | 2025 | 3194 | 0.520 |
Why?
| | Hypercalcemia | 1 | 2016 | 22 | 0.480 |
Why?
| | Vitamin D Deficiency | 2 | 2008 | 190 | 0.470 |
Why?
| | Paraganglioma | 1 | 2016 | 64 | 0.460 |
Why?
| | Multimodal Imaging | 1 | 2016 | 129 | 0.460 |
Why?
| | Quality of Health Care | 1 | 2020 | 692 | 0.450 |
Why?
| | Choroid Neoplasms | 1 | 2015 | 9 | 0.450 |
Why?
| | Neuroendocrine Tumors | 4 | 2021 | 119 | 0.450 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 666 | 0.450 |
Why?
| | Mediastinal Neoplasms | 1 | 2015 | 53 | 0.430 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 77 | 0.430 |
Why?
| | Relaxin | 2 | 2024 | 18 | 0.430 |
Why?
| | Testosterone | 1 | 2018 | 415 | 0.410 |
Why?
| | Thyrotropin | 3 | 2025 | 120 | 0.410 |
Why?
| | Humans | 57 | 2025 | 145140 | 0.410 |
Why?
| | Thyroxine | 2 | 2025 | 65 | 0.410 |
Why?
| | Spouses | 2 | 2018 | 108 | 0.400 |
Why?
| | Immunoglobulin G | 1 | 2018 | 887 | 0.400 |
Why?
| | Neoplasms | 5 | 2025 | 2900 | 0.390 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1579 | 0.370 |
Why?
| | Middle Aged | 23 | 2025 | 36126 | 0.370 |
Why?
| | Lymph Nodes | 1 | 2015 | 502 | 0.360 |
Why?
| | Adult | 25 | 2025 | 40665 | 0.350 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 161 | 0.350 |
Why?
| | Adrenal Insufficiency | 2 | 2023 | 31 | 0.340 |
Why?
| | Thyroid Hormones | 2 | 2020 | 68 | 0.310 |
Why?
| | Biomarkers, Tumor | 4 | 2024 | 1320 | 0.290 |
Why?
| | Gastric Bypass | 2 | 2008 | 126 | 0.290 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2021 | 98 | 0.280 |
Why?
| | Vitamins | 2 | 2010 | 182 | 0.270 |
Why?
| | Body Weight | 1 | 2012 | 969 | 0.260 |
Why?
| | Medical Oncology | 3 | 2021 | 338 | 0.260 |
Why?
| | Prospective Studies | 8 | 2025 | 8035 | 0.260 |
Why?
| | Obesity, Morbid | 2 | 2008 | 289 | 0.250 |
Why?
| | Iodine Radioisotopes | 3 | 2022 | 136 | 0.230 |
Why?
| | Male | 23 | 2025 | 72664 | 0.230 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2024 | 264 | 0.220 |
Why?
| | Female | 24 | 2025 | 78636 | 0.220 |
Why?
| | Aged | 11 | 2025 | 26096 | 0.220 |
Why?
| | Iowa | 3 | 2018 | 31 | 0.210 |
Why?
| | North Carolina | 3 | 2018 | 129 | 0.210 |
Why?
| | Blood Glucose | 6 | 2021 | 2335 | 0.200 |
Why?
| | Endocrine System Diseases | 1 | 2024 | 35 | 0.200 |
Why?
| | Hypoglycemic Agents | 2 | 2011 | 1393 | 0.200 |
Why?
| | Retrospective Studies | 12 | 2025 | 17247 | 0.200 |
Why?
| | Monitoring, Ambulatory | 1 | 2004 | 89 | 0.200 |
Why?
| | Insulin Resistance | 2 | 2011 | 1244 | 0.200 |
Why?
| | Menstrual Cycle | 1 | 2004 | 145 | 0.190 |
Why?
| | Hypophysitis | 1 | 2023 | 3 | 0.190 |
Why?
| | Postoperative Care | 3 | 2020 | 286 | 0.190 |
Why?
| | Cholecalciferol | 2 | 2014 | 61 | 0.190 |
Why?
| | Adenoma | 1 | 2025 | 218 | 0.190 |
Why?
| | Iodine | 1 | 2022 | 27 | 0.180 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2022 | 36 | 0.180 |
Why?
| | Bone Diseases, Metabolic | 1 | 2002 | 58 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 243 | 0.180 |
Why?
| | Urticaria | 2 | 2014 | 38 | 0.180 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2662 | 0.170 |
Why?
| | Asthenia | 1 | 2021 | 3 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2024 | 407 | 0.170 |
Why?
| | Insulin | 2 | 2011 | 2510 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 198 | 0.160 |
Why?
| | Radiation-Protective Agents | 1 | 2019 | 17 | 0.150 |
Why?
| | United States | 6 | 2025 | 16065 | 0.150 |
Why?
| | Metalloporphyrins | 1 | 2019 | 63 | 0.150 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 257 | 0.150 |
Why?
| | Hyperthyroidism | 1 | 2019 | 22 | 0.140 |
Why?
| | Lutein | 1 | 2019 | 16 | 0.140 |
Why?
| | Zeaxanthins | 1 | 2019 | 19 | 0.140 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 205 | 0.140 |
Why?
| | Chromatography, Liquid | 2 | 2018 | 450 | 0.140 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 412 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 407 | 0.140 |
Why?
| | Radioimmunoassay | 1 | 2018 | 165 | 0.140 |
Why?
| | Capital Financing | 1 | 2017 | 7 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1264 | 0.130 |
Why?
| | Training Support | 1 | 2017 | 35 | 0.130 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 120 | 0.130 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2019 | 178 | 0.130 |
Why?
| | Mutation | 2 | 2019 | 4071 | 0.120 |
Why?
| | Age Factors | 1 | 2024 | 3338 | 0.120 |
Why?
| | Fetal Blood | 1 | 2019 | 325 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 497 | 0.120 |
Why?
| | Succinate Dehydrogenase | 1 | 2016 | 65 | 0.120 |
Why?
| | Macrophages | 1 | 2024 | 1500 | 0.120 |
Why?
| | Melanoma | 1 | 2023 | 759 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5411 | 0.110 |
Why?
| | Transplantation | 1 | 2015 | 33 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2018 | 728 | 0.110 |
Why?
| | Universities | 1 | 2017 | 443 | 0.110 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 299 | 0.110 |
Why?
| | Risk Assessment | 1 | 2024 | 3740 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 967 | 0.100 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 1092 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2024 | 3539 | 0.100 |
Why?
| | Sepsis | 1 | 2020 | 662 | 0.100 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 688 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1146 | 0.100 |
Why?
| | DNA Adducts | 1 | 2013 | 16 | 0.100 |
Why?
| | Cholestanetriol 26-Monooxygenase | 1 | 2012 | 7 | 0.090 |
Why?
| | Steroid Hydroxylases | 1 | 2012 | 19 | 0.090 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2012 | 16 | 0.090 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2012 | 12 | 0.090 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 18 | 0.090 |
Why?
| | TATA-Box Binding Protein | 1 | 2012 | 20 | 0.090 |
Why?
| | Obesity | 2 | 2004 | 3097 | 0.090 |
Why?
| | Pilot Projects | 2 | 2008 | 1889 | 0.090 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2024 | 231 | 0.090 |
Why?
| | Calcitriol | 1 | 2012 | 57 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 562 | 0.090 |
Why?
| | Postoperative Complications | 2 | 2021 | 2961 | 0.090 |
Why?
| | Prevalence | 2 | 2010 | 2855 | 0.090 |
Why?
| | Triiodothyronine | 1 | 2011 | 54 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 267 | 0.090 |
Why?
| | Signal Transduction | 1 | 2024 | 5208 | 0.080 |
Why?
| | Diet | 1 | 2019 | 1277 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2021 | 2578 | 0.080 |
Why?
| | Environmental Exposure | 2 | 2018 | 577 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 367 | 0.080 |
Why?
| | Fumigation | 1 | 2010 | 3 | 0.080 |
Why?
| | Fungicides, Industrial | 1 | 2010 | 4 | 0.080 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2010 | 81 | 0.080 |
Why?
| | Herbicides | 1 | 2010 | 27 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2014 | 582 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2014 | 479 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 6055 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2018 | 11741 | 0.070 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2008 | 12 | 0.070 |
Why?
| | Parathyroid Hormone | 1 | 2008 | 114 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2026 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2004 | 3918 | 0.060 |
Why?
| | Dermatitis, Atopic | 1 | 2010 | 322 | 0.060 |
Why?
| | Disease Management | 2 | 2025 | 651 | 0.060 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1467 | 0.060 |
Why?
| | Creatinine | 1 | 2008 | 513 | 0.060 |
Why?
| | Internship and Residency | 1 | 2017 | 1264 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1442 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2504 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2024 | 68 | 0.050 |
Why?
| | Hospitalization | 1 | 2015 | 2458 | 0.050 |
Why?
| | Logistic Models | 1 | 2010 | 2133 | 0.050 |
Why?
| | Receptors, Peptide | 1 | 2024 | 18 | 0.050 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2024 | 66 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5886 | 0.050 |
Why?
| | Inpatients | 2 | 2021 | 552 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 376 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2915 | 0.050 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2002 | 26 | 0.050 |
Why?
| | Weight Loss | 1 | 2008 | 845 | 0.050 |
Why?
| | Gastroplasty | 1 | 2002 | 32 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3892 | 0.050 |
Why?
| | Hormones | 1 | 2023 | 135 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 105 | 0.050 |
Why?
| | Thyroglobulin | 1 | 2022 | 29 | 0.050 |
Why?
| | Calcium | 1 | 2008 | 1189 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2004 | 422 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2022 | 36 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2588 | 0.040 |
Why?
| | Antigens, CD | 1 | 2024 | 558 | 0.040 |
Why?
| | Risk Factors | 4 | 2019 | 10857 | 0.040 |
Why?
| | Ultrasonography | 1 | 2025 | 784 | 0.040 |
Why?
| | Thyroiditis | 1 | 2020 | 4 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2025 | 1506 | 0.040 |
Why?
| | Radiography | 1 | 2002 | 852 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1058 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1995 | 0.040 |
Why?
| | Salivary Glands | 1 | 2019 | 36 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 819 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Beta-Cryptoxanthin | 1 | 2019 | 2 | 0.040 |
Why?
| | beta Carotene | 1 | 2019 | 20 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2115 | 0.040 |
Why?
| | Xanthophylls | 1 | 2019 | 19 | 0.040 |
Why?
| | Carotenoids | 1 | 2019 | 47 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 41 | 0.040 |
Why?
| | Diet Surveys | 1 | 2019 | 90 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2023 | 531 | 0.030 |
Why?
| | Immunotherapy | 1 | 2023 | 665 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 223 | 0.030 |
Why?
| | Chronic Disease | 2 | 2014 | 1806 | 0.030 |
Why?
| | Young Adult | 3 | 2019 | 14176 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1325 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2021 | 699 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 769 | 0.030 |
Why?
| | Cetirizine | 1 | 2014 | 2 | 0.030 |
Why?
| | Ranitidine | 1 | 2014 | 14 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 84 | 0.030 |
Why?
| | Acetates | 1 | 2014 | 78 | 0.020 |
Why?
| | Sulfides | 1 | 2014 | 92 | 0.020 |
Why?
| | Quinolines | 1 | 2014 | 190 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 979 | 0.020 |
Why?
| | Placenta | 1 | 2019 | 784 | 0.020 |
Why?
| | Medicare | 1 | 2017 | 902 | 0.020 |
Why?
| | Cathelicidins | 1 | 2010 | 40 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 571 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4310 | 0.020 |
Why?
| | Animals | 2 | 2024 | 37952 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5988 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 261 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1958 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5972 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 862 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 6435 | 0.020 |
Why?
| | Disease Progression | 1 | 2014 | 2857 | 0.010 |
Why?
| | Pregnancy | 1 | 2019 | 7182 | 0.010 |
Why?
| | Glyburide | 1 | 2004 | 31 | 0.010 |
Why?
| | Adolescent | 1 | 2004 | 22479 | 0.010 |
Why?
| | Leptin | 1 | 2004 | 248 | 0.010 |
Why?
| | Adiponectin | 1 | 2004 | 241 | 0.010 |
Why?
| | Linear Models | 1 | 2004 | 844 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2004 | 608 | 0.010 |
Why?
| | Metformin | 1 | 2004 | 327 | 0.010 |
Why?
| | Body Composition | 1 | 2004 | 690 | 0.010 |
Why?
| | Lipids | 1 | 2004 | 706 | 0.010 |
Why?
| | Sex Factors | 1 | 2004 | 2099 | 0.010 |
Why?
|
|
Goldner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|